A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of Dose Limiting Toxicities (DLT) in the dose escalation part
Incidence and frequency of DLT during the first cycle of INC280 treatment in the dose escalation part according to the CTCAE.
4 weeks
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Japan: Pharmaceuticals and Medical Devices Agency
CINC280X1101
NCT01546428
February 2012
March 2015
Name | Location |
---|